Showing results (21-30 of 48) with videos related to

Sort By:
Pageof 5
Neuropsychiatric Disease and Treatment|March 14, 2019
Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European populationAdam J Savitz, Haiyan Xu, Srihari Gopal, et al.
The Annals of Pharmacotherapy|September 6, 2012
An analysis of potentially prolactin-related adverse events and abnormal prolactin values in randomized clinical trials with paliperidone palmitateThomas R Einarson, Michiel E H Hemels, Isaac Nuamah, et al.
Nursing Research|May 2, 2002
Describing an episode of home nursing care for elderly postsurgical cancer patientsLinda C Hughes, Linda A Robinson, Mary E Cooley, et al.
CNS Drugs|June 30, 2017
Evaluation of Potentially Prolactin-Related Adverse Events and Sexual Maturation in Adolescents with Schizophrenia Treated with Paliperidone Extended-Release (ER) for 2 Years: A Post Hoc Analysis of an Open-Label Multicenter StudySrihari Gopal, Rosanne Lane, Isaac Nuamah, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|March 1, 2014
Relapse prevention study of paliperidone extended-release tablets in Chinese patients with schizophreniaQing Rui, Yang Wang, Shu Liang, et al.
Neuropsychiatric Disease and Treatment|May 10, 2011
Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophreniaSrihari Gopal, Joris Berwaerts, Isaac Nuamah, et al.
Neuropsychiatric Disease and Treatment|December 1, 2018
Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitateMaju Mathews, Isaac Nuamah, Adam J Savitz, et al.
Psychopharmacology Bulletin|October 15, 2016
Efficacy and Safety of Paliperidone Extended Release 1.5 mg/day-A Double-blind, Placebo- and Active-Controlled, Study in the Treatment of Patients with SchizophreniaDanielle Coppola, Rama Melkote, Caroline Lannie, et al.
Current Drug Safety|November 5, 2010
Are the long-acting intramuscular formulations of risperidone or paliperidone palmitate associated with post-injection delirium/sedation syndrome? An assessment of safety databasesLarry Alphs, Srihari Gopal, Keith Karcher, et al.
Annals of African Medicine|May 10, 2019
A comparative study of the efficacy of intravenous benzylpenicillin and intravenous augmentin in the empirical management of Ludwig's anginaMatthew Owusu Boamah, Birch Dauda Saheeb, Grace E Parkins, et al.
Pageof 5